Tag Archives: PBMs

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Posted in Biotech, Corporate Responsibility, Guest Blog, healthcare, Market Access, pricing, Strategy | Also tagged , , , , , , , | 1 Comment

Obama Administration Halts Attack on Medicare Drug Plans

In an abrupt about-face, the Obama administration halted its ill-timed effort to launch an overhaul of the Medicare Part D program and announced it would not pursue changes in some key rules as proposed earlier this year. CMS had issued a proposed rule January 10 to drop “protected” class status for antidepressants and immunosuppressants in […]
Posted in FDA, healthcare, Legal, Market Access | Also tagged , , , , , , | Leave a comment

The Vanishing Rx Patient Assistance Programs?

by Tom Norton In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In response to the Clinton’s charges that the industry was “price gouging,” my firm was proposing that we provide free prescription products to any patients who could not […]
Posted in Corporate Responsibility, Guest Blog, healthcare, Legal, Market Access, Patient Communication | Also tagged , , , , , , | 1 Comment

Belviq's Battle of the Bulge

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September. Perhaps the most significant development in obesity of late is the recognition by payers – […]
Posted in Advertising, FDA, Global, healthcare, Market Access, Marketing, Patient Communication, People, pricing, Regulatory, Safety, Sales, Strategy | Also tagged , , , , , , , , , , , , , | Leave a comment

Pharma Gains from Rule On Health Insurance Benefits

Recent change likely to boost drug coverage by plans, but with variation in formularies. Health plans offering coverage to individuals and small companies are more likely to cover multiple drugs in each class or category under revised regulations proposed by the Department of Health and Human Services in November. A key change in rules to […]
Posted in healthcare, Legal, Regulatory, Strategy | Also tagged , , , | Leave a comment
  • Categories

  • Meta